Trial Search Results

Selegiline Patch for Treatment of Nicotine Dependence

Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institute on Drug Abuse (NIDA)

Stanford Investigator(s):

Intervention(s):

  • Drug: Selegiline
  • Other: matching placebo

Phase:

Phase 2

Eligibility


Inclusion Criteria:

   - Smokes greater than 20 cigarettes per day

Exclusion Criteria:

   - History of Parkinson's disease, high blood pressure, or severe liver or kidney disease

   - Current substance abuse

   - Mental illness

   - Skin conditions that could interfere with patch use

   - Using antidepressant medications (e.g., levodopa/carbidopa, methyldopa, or any MAO
   inhibitor)

   - Pregnant or breastfeeding

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Joel Killen
6507259443
Not Recruiting